

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ciaffoni Joseph</u> (Last) (First) (Middle) C/O COLLEGIUM PHARMACEUTICAL, INC. 780 DEDHAM STREET, SUITE 800 (Street) CANTON MA 02021 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>COLLEGIUM PHARMACEUTICAL, INC</u> [COLL]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Operating Officer
	3. Date of Earliest Transaction (Month/Day/Year) 05/31/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/31/2018		M		64,821	A	\$8.22	174,089	D	
Common Stock	05/31/2018		S ⁽¹⁾		59,204	D	\$22.54 ⁽²⁾	114,885	D	
Common Stock	05/31/2018		S ⁽¹⁾		5,617	D	\$23.35 ⁽³⁾	109,268	D	
Common Stock	05/31/2018		F		6,205 ⁽⁴⁾	D	\$22.62	103,063	D	
Common Stock	06/01/2018		S ⁽¹⁾		14,862	D	\$22.48 ⁽⁵⁾	88,201	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock option (right to purchase)	\$8.22	05/31/2018		M			64,821	(6)	05/31/2027	Common Stock	64,821	\$0	194,462	D	

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2017.
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$22.10 to \$23.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5).
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$23.10 to \$23.45, inclusive.
- Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$22.14 to \$22.91, inclusive.
- 64,821 shares subject to the option vested and became exercisable on May 31, 2018. The remaining 194,462 shares subject to the option vest in equal quarterly installments (rounded up to the nearest whole share of common stock) over a three year period, subject to the reporting person's continued service with the issuer.

Remarks:

/s/ Paul Brannelly as Attorney- 06/04/2018
In-Fact For Joseph Ciaffoni

** Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.